⌕
Trevi Therapeutics · TRVI · Nasdaq
Tenet 53 · Mixed
Compare
$13.51+1.66%At closeTenet 53 · Mixed
$13.51+0.22 (+1.66%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Trevi Therapeutics (TRVI) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business enginePre-revenue: no positive revenue in any year through FY25, so the growth and margin read is withheld. Worth your attention in FY25: Share count (+108.8%) and Returns vs FCF (n/m). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)—
0.0
FY21→FY25CAGR —
Net income ($M)▲10.8%
−42.8
FY21→FY25CAGR —
Free cash flow ($M)▼10.0%
−42.1
FY21→FY25CAGR —
Diluted EPS▲31.9%
−0.32
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+108.8%

64.5mn → 134.7mn diluted shares since FY22. Rising share count dilutes EPS. Growth must outrun it.

Capex
$12.0K

−65.7% YoY in FY25.

Returns vs FCF
n/m

$0.8M returned vs $−42.1M of FCF in FY25. Free cash flow was negative, so returns were funded from the balance sheet rather than from cash generation.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)0.0Revenue0.0COGS0.0Gross profit−33.5R&D−15.8SG&A−49.3Op income6.6Tax & other−42.8Net income

Margin trend · direction beats level
108530%sector median net margin ~3%FY21FY25

This filer reports no gross profit or operating income line, so those margins are not drawn.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
—0.00.00.00.00.0——
Cost of revenue
—0.00.00.00.00.0——
Gross profit
—0.00.00.00.00.0——
Research & development
50,350.033,478.039,377.023,683.019,834.022,984.0▼15.0%+9.9%
Selling, general & admin
19,777.015,850.012,147.010,240.010,073.09,492.0▲30.5%+13.7%
Total operating expenses
70,127.049,328.051,524.033,923.029,907.032,476.0▼4.3%+11.0%
Operating incomefeeds ROC rank
−70,127.0−49,328.0−51,524.0−33,923.0−29,907.0−32,476.0▲4.3%—
Other income, net
9,295.06,505.03,583.04,826.0719.0−1,485.0——
Pretax income
−60,832.0−42,823.0−47,941.0−29,097.0−29,188.0−33,961.0▲10.7%—
Income tax
−75.0−64.0−30.0−32.0−36.0−21.0▼113.3%—
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−60,757.0−42,759.0−47,911.0−29,065.0−29,152.0−33,940.0▲10.8%—
Per share
Diluted EPSbuyback-sensitive
−0.39−0.32−0.47−0.29−0.45−1.49▲31.9%—
Diluted shares (mn)
159.73134.75101.9799.0364.5422.84▲32.1%+55.8%
Margins
† TTM = trailing four quarters through 2026-09-30.
FY18 – FY20 · 3 more years
Unlock the full history →
3 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-03-17 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.